Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?
Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?
You may also be interested in...
Avinger Invests In Trials Of Lumivascular Peripheral Atherectomy Device As Company Restructures
US FDA-approval for an in-stent restenosis trial of Avinger's Pantheris atherectomy system comes on the heels of positive results from the VISION trial of the Pantheris in patients with peripheral arterial disease of the lower extremities. Meanwhile, the company is restructuring to cut its expenses by half as its stock has been stuck below a dollar a share since April.
Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.